SHERIDAN, WYOMING – May 6, 2025 – BD (Becton, Dickinson and Company), a global leader in medical technology, has announced the induction of Eric Diebold, Ph.D., Vice President and General Manager of Instruments, Software, and Informatics, Biosciences, to the prestigious American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. This distinction, awarded to individuals who have made pioneering contributions to the field, underscores the significant role that Diebold has played in advancing medical and biological engineering, particularly in the realms of photonics, high-speed imaging, and flow cytometry.
AIMBE College of Fellows: A Prestigious Recognition in Medical and Biological Engineering
The AIMBE College of Fellows is an exclusive group, representing the top two percent of professionals in medical and biological engineering across academia, industry, clinical practice, and government. Diebold’s induction marks a milestone in his career and reinforces BD's leadership in driving innovation to improve global healthcare outcomes.
Joe Smith, MD, Ph.D., Senior Vice President and Chief Scientific Officer at BD, who nominated Diebold, expressed the significance of this honor: "AIMBE is the leading voice in medical and biological engineering, and their Fellows – which include Nobel Prize and Presidential Medal of Science winners – are at the forefront of driving innovation to improve the healthcare and safety of society. Eric Diebold is well deserving of the distinction, demonstrating a remarkable track record of commercializing innovation in the life sciences and developing the ideas, products, and people that can truly transform science and health."
Transforming the Study of Human Cellular Biology
Since joining BD in 2017, following the acquisition of his flow cytometry technology startup, Diebold has been a catalyst for breakthrough innovations. His work has led to the development of several groundbreaking products, such as the BD FACSDiscover™ S8 Cell Sorter, which features cutting-edge BD CellView™ Image Technology and BD SpectralFX™ Technology. These innovations have revolutionized the way scientists analyze human cells, enabling more precise and efficient studies of cellular biology.
The upcoming launch of the BD FACSDiscover™ A8 Cell Analyzer will build on these advancements, expanding the capabilities of flow cytometry technology to support a broader range of scientific experiments and discoveries. These innovations continue to have a transformative impact on the biosciences sector, empowering researchers to explore human biology at an unprecedented level of detail.
A Continued Commitment to Innovation
Diebold’s induction into the AIMBE College of Fellows not only celebrates his past contributions but also serves as a call to action for continued innovation. Reflecting on the honor, Diebold noted, "Induction into the AIMBE College of Fellows is a tremendous honor that reflects not my work alone but the collective efforts of the many great mentors, like Joe Smith, colleagues, and collaborators who have shaped my journey at BD and across my career. Joining this community is more than a recognition of past contributions, it is a call to continue innovating, advocating, educating, and inspiring the next generation of leaders in medical and biological engineering for the betterment of humanity."
BD’s Legacy of Excellence in Biosciences Innovation
Diebold is only the sixth BD associate to be inducted into the AIMBE College of Fellows, joining a distinguished group of leaders who have made significant contributions to the advancement of medical technology. He follows in the footsteps of BD executives such as John A. DeFord, Ph.D., Chief Technology Officer and Executive Vice President, BD, and Joe Smith, MD, Ph.D., Senior Vice President and Chief Scientific Officer, BD, among others.
With this induction, BD further cements its position at the forefront of medical and biological engineering, where its innovations continue to shape the future of healthcare. The company remains committed to advancing science and improving health outcomes through its state-of-the-art technologies and continued investment in cutting-edge research and development.